GlassScriptPhysician profile
Christopher A Trojanovich
NPI 1518087915
$1,668.73
in general payments reported to CMS, 2019-2025
17 companies · $230 in 2025
The $230 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $357 · 2021: $155 · 2022: $386 · 2023: $198 · 2024: $70.75 · 2025: $230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $498.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $580.51 | 2020-2025 | Repatha, Otezla, Repatha |
| Teva Pharmaceuticals USA, INC. | $237.25 | 2019-2020 | |
| Boston Scientific Corporation | $188.62 | 2022-2023 | Watchman Access System |
| W. L. Gore & Associates, INC. | $142.27 | 2019 | |
| Lilly USA, LLC | $121.52 | 2021-2025 | Zepbound |
| Amarin Pharma, INC. | $120.87 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $58.84 | 2020 | |
| Novartis Pharmaceuticals Corporation | $34.74 | 2025 | |
| Abbvie INC. | $31.53 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.43 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $25.14 | 2024 | Dupixent |
| Sumitomo Pharma America, INC. | $23.75 | 2025 | Gemtesa |
| Esperion Therapeutics, INC. | $19.96 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.78 | 2020 | |
| Eisai INC. | $14.35 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.28 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Trojanovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.